The stock of Second Sight Medical Products Inc (NASDAQ:EYES) is a huge mover today! The stock increased 7.98% or $0.26 during the last trading session, hitting $3.52. About 663,686 shares traded hands or 210.06% up from the average. Second Sight Medical Products Inc (NASDAQ:EYES) has declined 38.84% since February 26, 2016 and is downtrending. It has underperformed by 49.26% the S&P500.
The move comes after 8 months positive chart setup for the $144.98 million company. It was reported on Sep, 30 by Barchart.com. We have $5.70 PT which if reached, will make NASDAQ:EYES worth $89.89 million more.
Analysts await Second Sight Medical Products Inc (NASDAQ:EYES) to report earnings on November, 3. They expect $-0.16 earnings per share, down 23.08% or $0.03 from last year’s $-0.13 per share. After $-0.19 actual earnings per share reported by Second Sight Medical Products Inc for the previous quarter, Wall Street now forecasts -15.79% EPS growth.
According to Zacks Investment Research, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California.”
More notable recent Second Sight Medical Products Inc (NASDAQ:EYES) news were published by: Marketwatch.com which released: “Second Sight Medical Products Inc.” on May 17, 2011, also Quotes.Wsj.com with their article: “News Second Sight Medical Products Inc.EYES” published on February 15, 2011, Fool.com published: “Why Second Sight Medical Products Inc. Vaulted Higher Today” on February 27, 2015. More interesting news about Second Sight Medical Products Inc (NASDAQ:EYES) were released by: Fool.com and their article: “Why Second Sight Medical Products, Inc. Stock Bolted Higher Today” published on April 08, 2015 as well as Latimes.com‘s news article titled: “With ‘bionic eye’ booming, Second Sight is on analysts’ radar” with publication date: March 16, 2015.
EYES Company Profile
Second Sight Medical Products, Inc., incorporated on May 22, 2003, is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.